Celiac Disease Treatment Market Size, Share & Trends Analysis Report By Treatment (Vitamins & Minerals, Gluten-free Diet), By Route of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030

Celiac Disease Treatment Market Trends

The global celiac disease treatment market size was valued at USD 582.5 million in 2023 and is projected to grow at a CAGR of 11.8% from 2024 to 2030. This growth is attributed to the increasing prevalence of diagnosed cases, which has heightened the demand for effective treatments and diagnostic methods. In addition, growing public awareness regarding celiac disease symptoms and the importance of early diagnosis has led to more individuals seeking medical attention. Furthermore, the expanding gluten-free food industry supports the market by providing diverse dietary options. Advances in diagnostic technologies and ongoing research into new treatment modalities further contribute to market growth by improving the detection and management of the disease.

Governments of many nations are implementing various initiatives to create awareness about celiac disease and uplift the accessibility to diagnostics and treatment for every individual. For instance, some countries have conducted screening programs specifically targeting high-risk populations. In addition, point-of-care testing (POCT) for celiac disease has gained acceptance in the past few years because of its quick diagnostic proficiencies. This allows for timely diagnosis and enables early treatment, avoiding further severe risks to the patient. Along with increased disease awareness, key companies invest in drugs and gluten-free products to enhance patients' health and overall outcomes. The benefits of gluten-free products have led to the adoption and utilization of gluten-free items.

Furthermore, the market for celiac disease treatment is anticipated to expand worldwide, fueled by the development of anti-inflammatory drugs and therapeutic vaccines, rising healthcare expenditure, and continuous medical research, which further contribute to market growth. Adopting therapeutic products and rising diabetes cases in several countries is expected to surge market growth. In addition, R&D activities and expenditure for innovative treatment alternatives and practices executed by various healthcare organizations have opened more opportunities for market expansion of celiac disease treatment.

Treatment Insights

Vitamins and minerals dominated the market and accounted for the largest revenue share of 50.2% in 2023. This growth is driven by individuals with celiac disease, who often experience nutrient deficiencies due to the malabsorption of essential vitamins and minerals caused by intestinal damage. Supplementation with targeted vitamins and minerals helps address these deficiencies and supports overall health. Furthermore, the increasing availability of specialized vitamin and mineral supplements formulated for celiac patients has expanded treatment options. Rising awareness of the importance of proper nutrition in celiac disease management further contributes to the segment's growth.

Gluten-free diets are projected to grow at a CAGR of 10.8% over the forecast period. Individuals with celiac disease require a strict gluten-free diet to manage their symptoms. However, there is a growing demand for gluten-free products worldwide because of the increasing prevalence of celiac disease and other food allergies. Celiac disease is an autoimmune disorder caused by gluten-containing food consumption, leading to gut inflammation and other health issues. Moreover, individuals are increasingly focused on health and wellness, leading to a shift in dietary preferences. Nowadays, restaurants, cafés, and home-cooked are involved in increased consumption of gluten-free products such as bread, cookies, and other bakery items, resulting in market growth.

Route of Administration Insights

The oral route of administration led the market and accounted for the largest revenue share of 62.7% in 2023. Orally consumable medicines have attained huge acceptance as an effective method to control celiac disease, address symptoms, and minimize inflammation in the digestive tract. The oral route of administration includes gluten-free items as well as any prescription medications or supplements because the core of the celiac disease path is adherence to a rigorous gluten-free diet. Furthermore, in severe conditions, oral immunosuppressants such as azathioprine (Imuran) may be directed to control the immunological response. In addition, pharmaceutical companies focus on R&D to enhance new oral medicines that improve the health of patients engaged with celiac disease. This boosts the growth of the market during the forecast period.

The parenteral route of administration is expected to grow at a CAGR of 10.4% over the forecast period. This growth is attributed to the increasing recognition of celiac disease has led to a higher patient population requiring effective treatment options. Parenteral administration allows for rapid delivery of medications, particularly in patients who may have difficulty absorbing nutrients orally due to intestinal damage. Furthermore, advancements in drug formulations and the development of new therapies targeting celiac disease symptoms enhance the appeal of parenteral routes, driving their adoption in clinical settings.

Distribution Channel Insights

The hospitals dominated the market and held the largest revenue share of 50.4% in 2023, owing to the rising aging population, increasing prevalence of celiac diseases, and the need for betterment in healthcare. Hospitals are significant & crucial in the diagnosis, treatment, and management of celiac disease. They serve as primary sites for diagnostic procedures which help in the diagnosing and confirmation of celiac disease. It offers specialist assistance on treatment alternatives, such as gluten-free diet implementation, nutritional therapy with suitable dietary plans, and monitoring for any circumstances.

Research centers are expected to grow at a CAGR of 9.6% over the forecast period. The growth factors include a prominent rise and focus on investments in research and development for the treatment of celiac diseases. Key market players and governments are spending on newer medications and enhancing the capabilities of treatments and various drug clinical trials to obtain better results.

Regional Insights

North America celiac disease treatment market dominated the global market and accounted for the largest revenue share of 41.8% in 2023. This growth is attributed to the rising prevalence of celiac diseases, rising awareness among citizens, the presence of major companies, and a strong supply channel of medications in the region. In addition, with the consumption of gluten-containing foods, the prevalence of the disease is growing in the region, resulting in advanced and timely diagnosis of celiac diseases with the requirement of improved treatment options.

U.S. Celiac Disease Treatment Market Trends

The celiac disease treatment market in the U.S. dominated the North American market with a revenue share of 88.4% in 2023 attributed to the consumption of alcoholic beverages, and fast food increasing in the region, which is a major risk factor for all age groups, giving rise to celiac disease. In addition, packaged food with gluten and irregular dietary patterns are due to hectic work life, and an increasing preference for ready-to-eat food results in increasing diseases. Therefore, the high consumption of gluten-containing food and the prevalence of celiac diseases result in the need for celiac disease treatment, fueling the market during the forecast period.

Europe Celiac Disease Treatment Market Trends

Europe celiac disease treatment market is expected to grow significantly. This growth is driven by the rising number of geriatrics, more active lifestyles in European countries, and technological developments in healthcare. Furthermore, advancements in diagnostic technologies and a growing gluten-free food industry support market expansion. Increased healthcare expenditures further facilitate the development of new treatment options and improved patient care.

The celiac disease treatment market in the UK is expected to witness substantial growth over the forecast period. This growth is attributed to the increasing prevalence of celiac disease and other food allergies by citizens, which has resulted in demand for gluten-free products. In addition, the UK market is experiencing continuous growth due to the requirement for diagnosis and treatment of celiac diseases to prevent complexity, thereby propelling the market growth.

Asia Pacific Celiac Disease TreatmentMarket Trends

The Asia Pacific celiac disease treatment market is anticipated to grow at a CAGR of 13.1% over the forecast period. This growth is attributed to the increasing awareness about the disease and the increasing elderly population in countries such as India, China, Japan, and South Korea. Furthermore, the expanding gluten-free food industry also contributes significantly, alongside growing healthcare expenditures that support better treatment options and patient care.

The China celiac disease treatment market growth is expected to be driven by the increased awareness of celiac disease and its timely treatment, rising healthcare expenditures, suitable and strong economic conditions, and technical enhancements that drive the market. The major factor that propels the growth of the celiac disease treatment market in the country is the awareness of celiac disease among the citizens and the increasing elderly population. As more people become aware of celiac disease, they are likely to prefer early diagnostics and treatment, which is leading to increased demand for celiac disease treatment.

Key Celiac Disease Treatment Company Insights

Some of the key companies in the celiac disease treatment market include Teva Pharmaceutical Industries Ltd., Amgen Inc., Amneal Pharmaceuticals LLC., Glenmark Life Sciences Limited, Takeda Pharmaceutical Company Limited, and Hikma Pharmaceuticals PLC. These companies are in the market and are focusing on continuous development and innovation to gain a competitive edge in the industry.

• Amneal Pharmaceuticals LLC manufactures and distributes generic pharmaceuticals and serves the healthcare sector worldwide. The company offers prescription pharmaceutical products in several forms, including hormonal, potency formulations, soft gelatin capsules, tablets, liquids, and oral solids. They specialize in delivering medical products for central nervous system disorders, parasitic infections, and other therapeutic categories.

• Zydus Pharmaceuticals, Inc. provides pharmaceutical products and manufactures pharmaceutical ingredients and animal healthcare products. They market, package, and distribute tablets, capsules, soft gel, sterile liquids, and inhalers worldwide. The company also manufactures and markets healthcare solutions, including formulations, active pharmaceutical ingredients, vaccines, diagnostics, health and dietetic foods, cosmeceuticals, and animal healthcare.

Recent Developments

• In February 2024, Novartis received the FDA approval of Xolair (omalizumab) as the first and only medication for reducing allergic reactions in individuals aged one and older with IgE-mediated food allergies. This approval followed the successful Phase III OUtMATCH study, demonstrating that Xolair significantly helps patients tolerate small amounts of allergens including peanuts and milk.

Celiac Disease Treatment Market Report Scope

Global Celiac Disease Treatment Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and analyzes the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global celiac disease treatment market report based on treatment, route of administration, distribution channel, and region:

• Treatment Outlook (Revenue, USD Million, 2018 - 2030)

  • Vitamins & Minerals

  • Gluten-free Diet

  • Medical Therapies

    • Infliximab

    • Larazotide Acetate

    • Azathioprine

    • Budesonide

    • Others

• Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)

  • Oral

  • Parenteral

• Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

  • Hospitals

  • Research Centers

  • Others

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • Middle East and Africa (MEA)

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait